Maryland Attorney General Anthony G. Brown announced Monday that the state has finalized a settlement with drug manufacturer Indivior, providing more than $1.5 million in opioid abatement funds and an additional $2 million in medication to treat opioid use disorder.
Maryland alleged that Indivior, which manufactures buprenorphine products used to treat opioid addiction, improperly marketed its products and failed to monitor suspicious orders.
The settlement also places restrictions on the company’s marketing practices and prohibits tying sales employees’ compensation to the volume of opioid treatment products sold. The funding and medication will support treatment efforts across Maryland.
The full consent judgment is available through the Maryland Attorney General’s Office.